Try our Advanced Search for more refined results

In re: Effexor XR Antitrust

  1. August 21, 2017

    3rd Circ. Revives Lipitor, Effexor Antitrust Claims

    The Third Circuit on Monday handed a sweeping victory to buyers of cholesterol drug Lipitor and antidepressant drug Effexor XR, reviving their antitrust claims for alleged patent fraud and anti-competitive reverse payment schemes.

  2. May 18, 2017

    3rd Circ. Could Up Ante For Buyers In Pay-For-Delay Cases

    The Third Circuit will hear oral arguments Friday in a pair of pay-for-delay cases over the drugs Lipitor and Effexor that could heighten the standard needed to allege that agreements to settle pharmaceutical patent dispute litigation constitute so-called reverse payments that run afoul of antitrust law.

  3. September 27, 2016

    Drugmakers Tell 3rd Circ. To Punt Effexor To Fed. Circ.

    Drugmakers Wyeth and Teva told the Third Circuit that purchasers’ claims of a reverse payment scheme over the generic version of the antidepressant Effexor XR belonged before the Federal Circuit, in the second case heard by the appeals court Tuesday on pay-for-delay jurisdictional issues.

  4. April 15, 2016

    Buyers Urge 3rd Circ. To Reopen Effexor Pay-For-Delay Suit

    Drug buyers have urged the Third Circuit to revive antitrust claims against Wyeth and Teva over an alleged bribe to delay a generic version of the antidepressant Effexor XR, arguing the drugmakers’ patent licensing deal constitutes a large, unexplained reverse payment.

  5. November 12, 2015

    3rd Circ. Asked To Revive Effexor Pay-For-Delay Claims

    CVS, Rite Aid and other pharmacy retailers accusing Wyeth LLC of bribing Teva Pharmaceuticals USA Inc. to delay a generic version of the antidepressant Effexor have told the Third Circuit that their claims shouldn’t have been dismissed even though the alleged scheme didn’t involve cash payments.